Title:
HETEROCYCLIC COMPOUND USED AS FGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2017/118438
Kind Code:
A1
Abstract:
The present invention provides a heterocyclic compound used as a fibroblast growth factor receptor (FGFR) inhibitor. Specifically, the present invention provides a compound represented by formula (I), comprising an isomer (an enantiomer or a diastereoisomer) that may exist, or a pharmaceutically acceptable salt, a prodrug, a deuterated compound, a hydrate and a solvate thereof. Radical groups in the formula (I) are defined in specifications. The compound in the present invention has FGFR inhibitory activity, and can be used for preventing or treating diseases related to FGFR activity or expression quantity.
Inventors:
ZHANG HANCHENG (CN)
LIU SHIFENG (CN)
LIU SHIFENG (CN)
Application Number:
PCT/CN2017/070674
Publication Date:
July 13, 2017
Filing Date:
January 09, 2017
Export Citation:
Assignee:
HANGZHOU INNOGATE PHARMA CO LTD (CN)
International Classes:
C07D413/12; A61K31/506; A61K31/5383; A61P19/00; A61P35/00; A61P35/02; C07D239/48; C07D401/12; C07D403/12; C07D471/08; C07D498/04
Domestic Patent References:
| WO2015057938A1 | 2015-04-23 |
Foreign References:
| CN101336237A | 2008-12-31 |
Attorney, Agent or Firm:
XU & PARTNERS,LLC. (CN)
Download PDF: